Illumina shares have increased in value by about 40 percent in 2018.

Illumina shares have increased in value by about 40 percent in 2018.

Locally, billion dollar deals normally end with a San Diego firm being acquired. Tell that to Illumina.

In October, the company agreed to buy Bay Area-based Pacific Biosciences for $1.2 billion, a move analysts say will fortify Illumina’s genomics dominance.

Illumina’s “short-read” platform deciphers fragments of DNA and reassembles them, while Pacific Biosciences specializes in decoding lengthier DNA chunks. This will give Illumina a more complete view of the genome.

Another acquisition earlier in the year provided the company with a need for speed.

Illumina bought San Diego-based Edico Genome for $100 million, helping Illumina to quickly analyze the ever-growing amounts of data generated by its sequencers.

That could mean, for instance, faster test results for a doctor deciding on the best course of care.

Besides acquisitions, rising sales pumped up Illumina’s stock. Its shares traded at $313.58 on Dec. 19, up almost 40 percent from year’s beginning.

With new frontiers opening up in genomics, ex-Illumina executives have formed their own companies. Most of at least nine local upstarts with an Illumina pedigree have surfaced in the last two years, as covered in a September San Diego Business Journal article.